- 作者：Ni-Chung Lee ; Ling-Yee Cheng ; Tze-Tze Liu ; Kwang-Jen Hsiao ; Pao-Chin Chiu and Dau-Ming Niu
- 刊名：Molecular Genetics and Metabolism
- 出版年：2006
- 出版时间：February 2006
- 年：2006
- 卷：87
- 期：2
- 页码：128-134
- 全文大小：279 K
Objectives6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency is the most important type of BH4 deficiency related to hyperphenylalaninemia. PTPS deficiency may not only cause a typical phenylketonuric phenotype, but is also accompanied by various neurological signs and symptoms due to impaired synthesis of catecholamines and serotonin. Reports of the long-term outcomes of these patients, especially after delayed onset of therapy, are few.Study design
We reviewed the characteristics of 10 PTPS-deficient patients whose treatment onset with tetrahydrobiopterin, l-DOPA, and hydroxytryptophan had been delayed. The relationships among clinical manifestations, biochemical findings, genotypes, and long-term outcomes were analyzed.
Results
We classified eight patients as having severe forms, and two as having moderate forms of PTPS deficiency. Improvements in neurological status and intelligence/developmental quotient (IQ/DQ) were observed in all patients, up to approximately 15 years of follow-up. One patient began walking and talking after 4 years of treatment. In patients with severe disease, the mean initial IQ/DQ was 45.40 ± 13.94, and the final full-scale intelligence quotient (FIQ) score was 62.8 ± 13.06 (p = 0.042), with a mean increment of 17.4 ± 5.27 over 15.86 ± 4.85 years of follow-up. Two patients with moderately severe disease had FIQ increases from 75 to 77 and from 76 to 80 points, respectively.
Conclusions
The administration of neurotransmitters based on clinical response and adverse effects was beneficial in patients whose treatment of PTPS deficiency was delayed. Sustained clinical improvements were observed up to 15 years of follow-up.